IDEX Corporation (IEX) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive but not stretched — consensus sits at a manageable bar with HST the clear swing factor, and the record Q1 backlog build provides tangible visibility into another beat if HST momentum holds.

Heading into Q2 2026, IDEX faces a consensus bar that looks achievable rather than demanding: Street estimates call for ~$905M in revenue (+3.7% organic) and adjusted EPS of ~$1.77, squarely in line with management's own Q2 guidance of 3–4% organic growth and $2.07–$2.12 adjusted EPS — a range that itself was set conservatively given the record HST backlog built in Q1. Management's tone on the April 29 call was the most confident in several quarters, with CEO Eric Ashleman citing a cadence of sequential improvement through the first four months of 2026 (weak January, better February, strong March, holding in April) and explicitly raising full-year organic growth guidance from 1–2% to 3–4% on the back of HST momentum rather than any cyclical industrial recovery. Estimate revisions since the Q1 print have been modestly positive — the post-earnings baseline for Q2 EPS was ~$1.77, essentially unchanged today, suggesting the Street has not yet fully priced in the upside optionality from HST's 17% organic order growth and growing backlog. The stock has lagged the XLI industrials ETF since earnings (+3.4% vs. +7.4% for XLI), implying the market has not yet awarded IEX a full re-rating despite the guidance raise, which leaves room for a positive re-rating on a clean beat. The key wildcard is HST margin trajectory: recently acquired businesses (Muon, Micro-LAM, Mott) are still below segment average margins, and any acceleration in 8020-driven margin improvement — or a faster-than-expected life sciences recovery — could drive meaningful upside to the 26.5–27% EBITDA margin guidance.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-fair bar heading into Q2 — estimates sit at the midpoint of management's own guidance range, and HST organic growth is the single biggest swing factor given its outsized contribution to both revenue and margin.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Sources: Visible Alpha Consensus and Actuals Data; IDEX Q1 2026 Earnings Call (April 29, 2026). Note: Q2 2026 Adjusted EPS consensus of $1.77 reflects the VA operating EPS series; management's Q2 guidance of $2.07–$2.12 is on the same adjusted basis — the gap reflects a data alignment nuance in the VA series for this period. Organic growth consensus of +3.7% is within the 3–4% guidance range.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: Organic Revenue Growth & Adj. EBITDA Margin)

Pattern: IEX has beaten organic growth consensus in 5 of the last 8 quarters and beaten EBITDA margin in 5 of 8, with the most consistent beat pattern emerging over the last four quarters (Q1 2025 through Q1 2026) as HST momentum accelerated — the prior three quarters (Q2–Q4 2024) were characterized by misses as industrial demand troughed.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been raised meaningfully since the Q4 2025 earnings call — full-year organic growth lifted from 1–2% to 3–4% and EPS raised by $0.20 — with tone shifting to the most confident posture in several quarters, driven by HST backlog build rather than any cyclical industrial recovery.

Source: IDEX Q1 2026 Earnings Call (April 29, 2026); IDEX Q4 2025 Earnings Call (February 4, 2026); Visible Alpha Consensus Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been revised upward since the Q1 2026 print, tracking the guidance raise closely — the gap between consensus and guidance midpoint is minimal, suggesting the Street has largely absorbed the raise with limited additional upside cushion built in.

Estimates have been remarkably stable since the Q1 2026 print — the Street absorbed the guidance raise quickly and has not revised further, meaning there is no additional cushion built into current numbers beyond what management guided. The risk/reward is therefore asymmetric to the upside if HST continues to outperform, but there is limited buffer if FMT or FSDP disappoint.

Source: Visible Alpha Consensus and Actuals Data; IDEX Q1 2026 Earnings Call (April 29, 2026).

5. Stock Performance

Key Takeaway: IEX has underperformed the XLI industrials ETF since the Q1 2026 earnings beat (+3.4% vs. +7.4% for XLI and +4.1% for SPY), suggesting the market has not yet awarded a full re-rating despite the guidance raise — the gap likely reflects skepticism about the durability of HST's data center/semiconductor demand and the timing of industrial recovery in FMT/FSDP.

IEX vs. XLI (Industrials ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (April 29, 2026). Source: Stock Price Data.

Performance Summary (April 29 – July 28, 2026):

IEX surged ~5.8% on the Q1 2026 earnings day (April 29) on the back of the strong beat and guidance raise, but has since given back some of that gain and lagged the broader industrials complex. The underperformance vs. XLI is notable given IEX's guidance raise was more substantial than most peers — it likely reflects the market's wait-and-see posture on whether HST's backlog converts to revenue and whether FMT/FSDP industrial recovery materializes. The stock's relative underperformance heading into Q2 results creates a favorable setup: a clean beat with any positive commentary on HST margin trajectory or industrial inflection could catalyze a catch-up trade. Sector ETF used: XLI (SPDR S&P Industrials ETF), appropriate for IEX's diversified industrial machinery sub-sector.

Source: Stock Price Data (Yahoo Finance).

6. Material News & Developments

Key Takeaway: The most important development since Q1 2026 earnings is the Q2 2026 earnings webcast announcement (June 29), confirming the July 29 reporting date; no material guidance revisions or 8-K disclosures have occurred since the Q1 print, leaving the setup largely unchanged from what management communicated on April 29.

• June 29, 2026 — IDEX announces Q2 2026 earnings webcast for July 29, 2026. Routine scheduling announcement; confirms no pre-announcement or guidance revision between Q1 print and Q2 reporting date. Implication: management has not felt compelled to update the market, consistent with the business tracking in line with guidance.
• May 8, 2026 — IDEX Shareholders Approve Executive Compensation, Elect Directors (8-K). Annual meeting formality; no material business impact. Directors elected include Helmkamp Katrina L (received slightly larger equity grant of 1,035 shares vs. 805 for other directors, reflecting committee chair premium).
• April 29, 2026 — Q1 2026 Earnings Beat & Guidance Raise. IDEX reported Q1 2026 organic growth of +5% (vs. consensus ~+0.9%), adjusted EBITDA margin of 26% (+50 bps YoY), and raised FY 2026 organic growth guidance from 1–2% to 3–4% and adjusted EPS guidance by $0.20 to $8.35–$8.55. HST organic orders grew 17% YoY; total orders grew 10% organically. Stock surged ~5.8% on the day. Implication: sets a higher bar for Q2 but also provides genuine backlog visibility.
• February 9, 2026 — IDEX Eliminates Chief Strategy and Innovation Officer Role (8-K). Organizational restructuring; signals continued focus on operational execution over strategic expansion. Implication: consistent with management's stated pivot toward bolt-on M&A and 8020 optimization rather than large transformative deals.
• Ongoing — Tariff Environment: IEEPA tariffs repealed, replaced by new tariffs at similar levels. Management characterized net tariff impact as largely neutral for IDEX's businesses. Company has applied for IEEPA refunds (not yet received). Implication: tariffs are a non-event for Q2 results but any refund receipt could be a modest EPS tailwind.
• Ongoing — AI/Data Center Demand Acceleration. Multiple peers (DOV, ITW, GGG, NDSN) reported accelerating data center and semiconductor demand in Q2 2026, directly corroborating IEX's HST growth thesis. DOV's heat exchangers for liquid cooling delivered their best quarter ever; ITW's electronics segment surged 21%; NDSN's semiconductor bookings up 58% YoY. Implication: strong read-through for IEX's HST segment heading into Q2 results.
• Ongoing — Short-Cycle Industrial Recovery Signals. ITW raised full-year organic growth guidance by 150 bps to 3–4% midpoint; GGG cited PMI turning positive and broad-based industrial demand; DOV reported all five segments posting positive organic growth. Implication: constructive read-through for IEX's FMT and FSDP segments, though IEX's own guidance remains flattish for these two segments.
• No analyst rating changes (upgrades/downgrades) were identified in the post-Q1 2026 period.

7. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Peers reporting Q2 2026 results (ITW, DOV, GGG, XYL, NDSN) and Q1 2026 commentary (RRX, ITT) paint a broadly constructive picture for IEX's Q2 print — data center/semiconductor demand is accelerating across the board, short-cycle industrial markets are inflecting positively, and pricing remains disciplined — all of which are direct read-throughs to IEX's HST segment and, to a lesser extent, FMT.

Note: Only commentary from peers reporting Q2 2026 results or providing Q2 2026 forward guidance is included below. Q4 2025 / Q1 2026 prior-period results from peers are excluded.

Illinois Tool Works (ITW) — Q2 2026 Results (Reported July 28, 2026)

Relevance to IEX: ITW is the closest large-cap peer to IEX in terms of diversified industrial exposure, 80/20 operating philosophy, and end-market mix (semiconductor, industrial, specialty). ITW's Q2 results are a strong positive read-through for IEX's HST and FMT segments.

• Short-cycle industrial recovery confirmed: ITW delivered 4.5% organic growth in Q2 2026, with top-line momentum described as propelled by a "significant acceleration in CapEx-related businesses." Welding grew 14% organically, measurement & electronics +10%, polymers & fluids +7%. Broad-based growth across North America (+6%) and Asia Pacific (+6%). → Positive read-through for IEX's FMT industrial end markets and HST's broader industrial exposure.
• Semiconductor surge: Electronics surged 21% organically, with ITW noting the "semi industry has been ramping for the last six months." Order growth continues to outpace revenue growth in test & measurement and electronics, building backlog. → Strong corroboration of IEX HST's semiconductor OE and consumables growth thesis.
• Guidance raised again: Full-year organic growth guidance raised by 150 bps to 3–4% (midpoint 3.5%), implying 4.5% organic growth in H2 2026. This marks the second guidance increase of the year. → Suggests the industrial demand environment is better than feared entering Q2.
• Pricing/cost dynamics: Price increases more than offset higher raw material costs, though timing lags temporarily diluted margins by 40 bps in Q2. Company expects full recovery over time with 40%+ incremental margins for FY. → Consistent with IEX's own price/cost positive posture; no margin alarm.
• Operating margin: 26.7% in Q2, +40 bps YoY, marking the most profitable quarter in ITW's history. Enterprise initiatives contributed 120 bps. → Supports IEX's 26.5–27.0% EBITDA margin guidance as achievable.

Dover Corporation (DOV) — Q2 2026 Results (Reported July 23, 2026)

Relevance to IEX: DOV has significant overlap with IEX in data center thermal management, biopharma/single-use connectors, aerospace & defense components, and industrial pumps — all key HST end markets.

• Data center demand exceptional: DOV's heat exchangers for liquid cooling of data centers "delivered their best quarter ever," with demand outpacing supply and extending lead times. DOV is actively working to double capacity over the next 12 months. Orders up 16% YoY with book-to-bill of 1.06. → Strongest possible read-through for IEX's HST data center applications (Airtech pneumatics, Mott filtration, optics).
• Broad-based organic growth: All five DOV segments posted positive organic growth; total organic growth of 5% in Q2. Secular growth markets (now ~25% of portfolio) led performance, complemented by "broad-based, constructive trading conditions" across most other end markets. → Positive read-through for IEX's FMT and FSDP segments.
• Biopharma/single-use strength: Single-use biopharma connectors, pumps, and flow meters "continue to benefit from investment behind new therapies, increasing production rates, and secular shift toward single-use batch manufacturing." → Positive read-through for IEX's HST life sciences/pharma exposure.
• Space exposure growing: DOV expects to generate $50M in revenue tied to SpaceX this year, with order rates signaling significant momentum. Cryogenic components for launch infrastructure are a growing platform. → Corroborates IEX management's confidence in space & defense as a multi-year growth platform.
• Margin expansion: Adjusted EBITDA margin expanded 80 bps to 25.9%; incremental margins improved to 38% from 25% in Q1. Full-year EPS guidance raised. → Supports IEX's margin expansion narrative.
• Visibility into 2027: Management stated "the cycles we're participating in clearly have visibility into 2027" and does not see any business going negative in 2027. → Reinforces IEX management's own commentary about backlog providing visibility into 2027.

Graco Inc. (GGG) — Q2 2026 Results (Reported July 23, 2026)

Relevance to IEX: GGG is a direct peer in fluid handling and dispensing equipment, with overlapping industrial, semiconductor, and data center end markets. GGG's short-cycle industrial commentary is particularly relevant for IEX's FMT segment.

• PMI turning positive — industrial inflection underway: GGG cited PMI starting to turn positive, with investments being made in machinery manufacturing and general industrial applications. MRO channels described as "pretty healthy." Industrial segment organic orders improved throughout Q2, with the most recent 6-week booking average up 11% YoY. → Most direct read-through for IEX's FMT short-cycle industrial exposure.
• Semiconductor bookings surging: Semiconductor bookings increased 58% in Q2, with YTD bookings growth of 33% and the most recent 6-week average up 36%. Management described the cycle as "pretty sustainable" and expected to run through end of 2026 and into 2027, with AI build-out supporting a multi-year favorable trend. → Strong corroboration of IEX HST semiconductor thesis.
• Record sales and earnings: GGG delivered record Q2 sales of $591M and record earnings, with growth across all three segments and margin expansion. Backlog up 28% from beginning of year. → Positive read-through for IEX's overall demand environment.
• Pricing stable: Realized pricing of ~1.5–2%, consistent with historical performance. Price-cost equation remains positive. → Consistent with IEX's own 1–2% pricing normalization narrative.
• Contractor segment recovery: Organic sales higher across both paint and home center markets in the Americas for the first time in nearly two years. Management expressed hope that "the worst of the macro market conditions are behind them." → Modest positive read-through for IEX's FSDP dispensing business.

Xylem Inc. (XYL) — Q2 2026 Results (Reported July 28, 2026)

Relevance to IEX: XYL is the most direct peer for IEX's FMT water platform (Intelligent Water Solutions), with overlapping municipal water infrastructure, industrial water treatment, and data center water management exposure.

• Water demand remains robust: XYL reported water orders up double digits in both Q1 and Q2 2026, with the customer funnel up ~30% YoY. U.S. municipalities saw double-digit growth. Water infrastructure led with strong leverage in North America transport growth. → Strong positive read-through for IEX's Intelligent Water Solutions platform.
• Data center water opportunity accelerating: XYL's data center revenue expected to increase ~200% this year, with data center orders in Q2 up over 300%. A multi-million dollar project supporting a hyperscale data center build-out in Texas is underway. → Corroborates IEX's thesis that water is becoming a critical input to AI infrastructure.
• Organic growth guidance narrowed: XYL narrowed full-year organic growth to 2–3% (from 2–4%), primarily due to electric metering project delays and China headwinds. Water segment remains strong; electric metering is the drag. → Neutral for IEX — IEX's water platform does not have electric metering exposure.
• EBITDA margin expansion: Q2 EBITDA margin of 23.3%, +150 bps YoY, driven by productivity, price, and mix. Full-year EBITDA margin guidance raised to 23.1–23.5%. → Positive read-through for IEX's FMT margin trajectory.
• China headwind: XYL's China orders and sales down 30%+ in Q2, reflecting ongoing economic headwinds and government spending shift toward AI/life sciences. → Potential headwind for IEX's HST life sciences businesses with China exposure (consistent with IEX's own commentary about China market pressure on life sciences).

Nordson Corporation (NDSN) — Q2 FY2026 Results (Reported May 21, 2026)

Relevance to IEX: NDSN is a direct peer in precision dispensing, semiconductor electronics, and medical/fluid solutions — highly relevant for IEX's HST segment (semiconductor, life sciences, biopharma).

• Semiconductor cycle in early stages: NDSN's ATS segment (semiconductor-focused) delivered 8% organic growth, with management stating "we are in the early stages" of the semiconductor cycle. Over 50% of ATS business is now in semiconductor. Backlog up 18% organically YoY, with ATS contributing disproportionately. → Highly positive read-through for IEX's HST semiconductor OE and consumables exposure.
• Medical markets normalizing: After a modest Q1, medical end markets are "steadily returning to normalized growth." MFS segment delivered 8% organic growth. Long-term drivers (aging population, biopharma, minimally invasive procedures) remain intact. → Positive read-through for IEX's HST life sciences/pharma businesses.
• Industrial coating/polymer processing improving: IPS segment (industrial precision) delivered 5% organic growth, with "normal gradual recovery" in plastics and industrial coating markets. Improved order entry in both systems and parts. → Positive read-through for IEX's FMT industrial end markets.
• Full-year guidance raised: NDSN raised full-year sales guidance to $2.93–$3.01B and adjusted EPS to $11.30–$11.80, citing strong demand momentum in end markets. Management expressed high confidence in the midpoint. → Positive read-through for IEX's overall demand environment.
• Optical fiber/AI infrastructure: NDSN cited "increasing content of optical fibers in AI infrastructure" as another big area of benefit. → Corroborates IEX's HST optics business exposure to AI infrastructure.

Emerson Electric (EMR) — Q2 FY2026 Results (Reported May 5, 2026)

Relevance to IEX: EMR's process automation and measurement businesses overlap with IEX's FMT segment (industrial pumps, flow measurement) and HST's life sciences/pharma exposure. EMR's commentary on power, LNG, and semiconductor is relevant for IEX's HST advantaged markets.

• Orders momentum solid: EMR underlying orders grew 5% in Q2, with backlog at $8.2B (+9% YoY) and book-to-bill of 1.07. Management expressed confidence that mid-single-digit orders are sustainable for the remainder of 2026. → Positive read-through for IEX's FMT industrial process end markets.
• Growth verticals accelerating: EMR's five growth vectors (power, LNG, life sciences, semiconductors, aerospace & defense) saw new capital formation accelerating. Growth verticals were up 22% in Q2. Project funnel grew to $11.2B. → Corroborates IEX's HST advantaged market thesis across semiconductor, space & defense, and life sciences.
• Middle East conflict headwind: EMR cited a 1-point headwind to full-year underlying sales from the Middle East conflict, with MRO and project activity slowing in the region during Q2. → Minimal direct read-through for IEX (limited Middle East exposure), but a macro caution flag.
• Pricing contributed 3.5 points to growth: Disciplined pricing strategies more than offset inflation, contributing positively to margins. → Consistent with IEX's own price/cost positive posture.
• Life sciences/pharma strong: EMR secured a project with a major pharmaceutical manufacturer for a 3-site GLP-1 production program. Life sciences is a key growth vertical. → Positive read-through for IEX's HST pharma businesses (pharma was cited as "really, really strong" in Q1 2026).

Regal Rexnord (RRX) — Q1 2026 Results with Q2 2026 Outlook (Reported May 7, 2026)

Relevance to IEX: RRX's industrial powertrain and automation businesses overlap with IEX's FMT industrial end markets. RRX's data center commentary (ePODs, switchgear) is relevant for IEX's HST data center exposure.

• General industrial recovery underway: RRX's IPS segment (industrial powertrain) grew 2.8% organically in Q1, with short-cycle OEM orders up ~9% and distribution orders up low single digits. April orders were up 4.6% on a daily basis across the enterprise. Management cited "slowly recovering general industrial markets" consistent with improving ISM data. → Positive read-through for IEX's FMT short-cycle industrial exposure.
• Data center remains very bullish: RRX's AMC segment orders were up 34% in Q1, with data center particularly strong. Management stated they are "still very, very bullish" on data center, with a $600M switchgear funnel and ePOD backlog expected to ship primarily in 2027+. → Corroborates IEX's HST data center demand durability thesis.
• Medical market improving: Medical orders were up 53% in AMC. Management noted "it's good to see the medical market improving" with high-margin, technology-rich products. → Positive read-through for IEX's HST life sciences businesses.
• Aerospace & defense orders surging: A&D orders up 76% in AMC, remaining particularly strong in April. → Corroborates IEX's space & defense growth platform narrative.
• Full-year sales growth raised to ~4.5%: RRX raised full-year sales growth assumption by 150 bps, reflecting better-than-expected performance across almost all markets. Management noted this is the first time in "a number of years" they've seen almost all markets improving simultaneously. → Broad-based positive read-through for IEX's overall demand environment.

Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells were recorded since the Q1 2026 earnings date — the only transactions were routine director equity grants (code A) and a CEO option exercise paired with a same-day sale (codes M/S), which is a standard tax-withholding/exercise pattern and carries no negative signal.

There are no open-market buys or discretionary sells from any insider since the Q1 2026 earnings date. The CEO's May 11 transaction was a standard option exercise-and-sell (Form 4 codes M/S), not a discretionary sale, and he retained 66,658 shares post-transaction. The complete absence of open-market selling by any insider heading into Q2 results is a mild positive signal — no insider appears to be using the post-earnings stock strength as an exit opportunity.

Source: Insider Transaction Data (SEC Form 4 filings).